相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma
Hee Seung Lee et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
AGE-RAGE synergy influences programmed cell death signaling to promote cancer
Bhargav N. Waghela et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2021)
Redox tolerance and metabolic reprogramming in solid tumors
Keywan Mortezaee
CELL BIOLOGY INTERNATIONAL (2021)
Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer
Keywan Mortezaee
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2021)
Steps in metastasis: an updated review
Jamal Majidpoor et al.
MEDICAL ONCOLOGY (2021)
Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion
Nicole E. Scharping et al.
NATURE IMMUNOLOGY (2021)
Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1α in cancer
Yu Fan Zhang et al.
PHYTOMEDICINE (2021)
CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells
Songyi Park et al.
FRONTIERS IN IMMUNOLOGY (2021)
Acriflavine, a Potent Inhibitor of HIF-1α, Disturbs Glucose Metabolism and Suppresses ATF4-Protective Pathways in Melanoma under Non-hypoxic Conditions
Roman Marti-Diaz et al.
CANCERS (2021)
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial
Akihito Kawazoe et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Roberta Zappasodi et al.
NATURE (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Modified Hypoxia-Inducible Factor Expression in CD8+ T Cells Increases Antitumor Efficacy
Pedro Velica et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy
Xin Peng et al.
FRONTIERS IN IMMUNOLOGY (2021)
Organ tropism in solid tumor metastasis: an updated review
Keywan Mortezaee
FUTURE ONCOLOGY (2021)
Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+T cells
Ilkka Liikanen et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K. Choueiri et al.
NATURE MEDICINE (2021)
Metabolic changes of Interleukin-12/15/18-stimulated human NK cells
Inigo Terren et al.
SCIENTIFIC REPORTS (2021)
The regulation of immune checkpoints by the hypoxic tumor microenvironment
Min Hu et al.
PEERJ (2021)
Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells
Nadia Bannoud et al.
FRONTIERS IN IMMUNOLOGY (2021)
An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment
Raefa Abou Khouzam et al.
FRONTIERS IN IMMUNOLOGY (2021)
Remodeling of Cancer-Specific Metabolism under Hypoxia with Lactate Calcium Salt in Human Colorectal Cancer Cells
Keun-Yeong Jeong et al.
CANCERS (2021)
PD-1-induced proliferating T cells exhibit a distinct transcriptional signature
Marianne Strazza et al.
IMMUNOLOGY (2021)
Interleukin-2 therapy of cancer-clinical perspectives
Jamal Majidpoor et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Hypoxia Enhances the Expression of RNASET2 in Human Monocyte-Derived Dendritic Cells: Role of PI3K/AKT Pathway
Sara Monaci et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer
Sakshi Taneja et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure
T. C. Lam et al.
LUNG CANCER (2021)
Hypoxia-induced lactate dehydrogenase A protects cells from apoptosis in endometriosis
Jinyan Zheng et al.
MOLECULAR MEDICINE REPORTS (2021)
Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors
Anli Zhang et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors
Marcel A. Schneider et al.
NATURE COMMUNICATIONS (2021)
Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21
Xuan Lin et al.
CANCERS (2021)
Perspectives on Hypoxia Signaling in Tumor Stroma
Yuqing Zhang et al.
CANCERS (2021)
Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases
He Hao et al.
INFLAMMATION AND REGENERATION (2021)
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination
Shereen El Shorbagy et al.
JOURNAL OF GASTROINTESTINAL CANCER (2021)
The 2019 Nobel Prize honors fundamental discoveries in hypoxia response
Javid Moslehi et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET ONCOLOGY (2020)
The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
Ryota Tamura et al.
MEDICAL ONCOLOGY (2020)
Microbe-MUC1 Crosstalk in Cancer-Associated Infections
Mukulika Bose et al.
TRENDS IN MOLECULAR MEDICINE (2020)
The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages
Eman Sami et al.
CANCER RESEARCH (2020)
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
Per Pfeiffer et al.
LANCET ONCOLOGY (2020)
Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1α and HIF-2α
Keywan Mortezaee
LIFE SCIENCES (2020)
Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity
Dalton Hermans et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis
Yaqing Zhang et al.
CANCER DISCOVERY (2020)
Bcl2 inhibitor ABT737 reverses the Warburg e ffect via the Sirt3-HIF1? axis to promote oxidative stress -induced apoptosis in ovarian cancer cells
Delu Dong et al.
LIFE SCIENCES (2020)
Hypoxia-Driven Immune Escape in the Tumor Microenvironment
Alyssa Vito et al.
CELLS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1 alpha and STAT3 in human colon cancer cells
Zhe Wang et al.
PHARMACOLOGICAL RESEARCH (2020)
The expressions of NLRP1, NLRP3, and AIM2 inflammasome complexes in the contusive spinal cord injury rat model and their responses to hormonal therapy
Jamal Majidpoor et al.
CELL AND TISSUE RESEARCH (2020)
Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway
Jukun Song et al.
FRONTIERS IN ONCOLOGY (2020)
Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer
Hong Xiang Zuo et al.
JOURNAL OF ETHNOPHARMACOLOGY (2020)
Toll-Iike Receptor-3 Activation Enhances Malignant Traits in Human Breast Cancer Cells Through Hypoxia-inducible Factor-1α
Francesca Scatozza et al.
ANTICANCER RESEARCH (2020)
Natural killer cells in cancer biology and therapy
Song-Yang Wu et al.
MOLECULAR CANCER (2020)
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Jackie E. Bader et al.
MOLECULAR CELL (2020)
Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors
Matthew I. Confeld et al.
MOLECULAR PHARMACEUTICS (2020)
Dendritic cell biology and its role in tumor immunotherapy
Yingying Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study
Masoud Najafi et al.
LIFE SCIENCES (2020)
Cancer immunotherapy via targeted TGF-β signalling blockade in THcells
Shun Li et al.
NATURE (2020)
Dynamic regulation of hypoxia-inducible factor-1α activity is essential for normal B cell development
Natalie Burrows et al.
NATURE IMMUNOLOGY (2020)
HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice
Rouven Hoefflin et al.
NATURE COMMUNICATIONS (2020)
HIF-2α is indispensable for regulatory T cell function
Tzu-Sheng Hsu et al.
NATURE COMMUNICATIONS (2020)
Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy
Joseph M. Steingold et al.
FRONTIERS IN IMMUNOLOGY (2020)
Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways
Yi-Na Liu et al.
FRONTIERS IN IMMUNOLOGY (2020)
The Production of Pro-angiogenic VEGF-A Isoforms by Hypoxic Human NK Cells Is Independent of Their TGF-β-Mediated Conversion to an ILC1-Like Phenotype
Lindsey G. Hawke et al.
FRONTIERS IN IMMUNOLOGY (2020)
Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development
Fatemeh Azizian-Farsani et al.
FRONTIERS IN ONCOLOGY (2020)
Systemic hypoxia inhibits T cell response by limiting mitobiogenesis via matrix substrate-level phosphorylation arrest
Amijai Saragovi et al.
ELIFE (2020)
Tumor Lactic Acidosis: Protecting Tumor by Inhibiting Cytotoxic Activity Through Motility Arrest and Bioenergetic Silencing
Angelika J. Fischbeck et al.
FRONTIERS IN ONCOLOGY (2020)
Hypoxia Induces Transcriptional and Translational Downregulation of the Type I IFN Pathway in Multiple Cancer Cell Types
Ana Miar et al.
CANCER RESEARCH (2020)
Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment
Lihong Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation
Ying Xiao et al.
CELL TRANSPLANTATION (2020)
Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment
Yun Ge et al.
PHYTOMEDICINE (2020)
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
Giacomo De Luca et al.
LANCET RHEUMATOLOGY (2020)
The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune
Salem Chouaib
CRITICAL REVIEWS IN IMMUNOLOGY (2020)
Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Disruption of the redox balance with either oxidative or anti-oxidative overloading as a promising target for cancer therapy
Bagher Farhood et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer
Qinchuan Wu et al.
HEPATOLOGY (2019)
Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors
Anna Schurich et al.
IMMUNOTHERAPY (2019)
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically
Shawn C. Chafe et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Jie Deng et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention
Ben Wylie et al.
CANCERS (2019)
The B-Side of Cancer Immunity: The Underrated Tune
Anne Largeot et al.
CELLS (2019)
Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop
Ke Xu et al.
MOLECULAR THERAPY (2019)
Allosteric inhibition of HIF-2 as a novel therapy for clear cell renal cell carcinoma
Yancheng Yu et al.
DRUG DISCOVERY TODAY (2019)
Hypoxia enhances IL-10-producing B cell generation through upregulating high-mobility group B1 on tumor cell-released autophagosomes
Yue Zhang et al.
IMMUNOLOGY LETTERS (2019)
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2019)
Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges
Muhammad Zaeem Noman et al.
CELLS (2019)
Targets for improving tumor response to radiotherapy
Keywan Mortezaee et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Xinming Jing et al.
MOLECULAR CANCER (2019)
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Christopher Groth et al.
BRITISH JOURNAL OF CANCER (2019)
Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
Nasser Hashemi Goradel et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Stromal reprogramming: A target for tumor therapy
Masoud Najafi et al.
LIFE SCIENCES (2019)
NADPH Oxidase as a Target for Modulation of Radiation Response; Implications to Carcinogenesis and Radiotherapy
Keywan Mortezaee et al.
CURRENT MOLECULAR PHARMACOLOGY (2019)
Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion
Nicholas C. DeVito et al.
FRONTIERS IN IMMUNOLOGY (2019)
Fusobacterium nucleatum and colorectal cancer: A mechanistic overview
Nasser Hashemi Goradel et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
S. K. Daniel et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2019)
Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Keywan Mortezaee et al.
CURRENT CLINICAL PHARMACOLOGY (2019)
Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors
Franziska Eckert et al.
FRONTIERS IN IMMUNOLOGY (2019)
SIRT1 and HIF1α signaling in metabolism and immune responses
Qing Yu et al.
CANCER LETTERS (2018)
Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer
Lifeng Li et al.
CANCER RESEARCH (2018)
TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy
Lan Huang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Hypoxia and acidosis: immune suppressors and therapeutic targets
Sultan Damgaci et al.
IMMUNOLOGY (2018)
Oxygen-dependent regulation of immune checkpoint mechanisms
Akio Ohta
INTERNATIONAL IMMUNOLOGY (2018)
Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy
Hiroaki Senju et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2018)
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
Janet Retseck et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hypoxia-Driven immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational immunotherapy
Yiliang Li et al.
FRONTIERS IN IMMUNOLOGY (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation
Arum Park et al.
FRONTIERS IN IMMUNOLOGY (2018)
Effects of curcumin on hypoxia-inducible factor as a new therapeutic target
Afsane Bahrami et al.
PHARMACOLOGICAL RESEARCH (2018)
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses
Alireza Saeidi et al.
FRONTIERS IN IMMUNOLOGY (2018)
B-Cell Metabolic Remodeling and Cancer
Davide G. Franchina et al.
TRENDS IN CANCER (2018)
Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer
Mao Lin et al.
IMMUNOLOGY LETTERS (2017)
Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma
Takafumi Minami et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET (2017)
Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
David Kung-Chun Chiu et al.
NATURE COMMUNICATIONS (2017)
Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis
Ewelina Krzywinska et al.
NATURE COMMUNICATIONS (2017)
CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function
Xi Chen et al.
ONCOTARGET (2017)
Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis
Erika M. Palmieri et al.
CELL REPORTS (2017)
CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF--mTOR-HIF-1 signaling in patients with non-small cell lung cancer
Jieyao Li et al.
ONCOIMMUNOLOGY (2017)
Hypoxia Enhances Immunosuppression by Inhibiting CD4(+) Effector T Cell Function and Promoting Treg Activity
Astrid M. Westendorf et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Tumour acidosis: from the passenger to the driver's seat
Cyril Corbet et al.
NATURE REVIEWS CANCER (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
HIF-1 at the crossroads of hypoxia, inflammation, and cancer
Kuppusamy Balamurugan
INTERNATIONAL JOURNAL OF CANCER (2016)
Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia
Kyoung Eun Lee et al.
CANCER DISCOVERY (2016)
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressionaEuro
R. Obermannova et al.
ANNALS OF ONCOLOGY (2016)
Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer
Nasim Kheshtchin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26
David Kung-Chun Chiu et al.
HEPATOLOGY (2016)
CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation
Vinit Kumar et al.
IMMUNITY (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dendritic Cells and Cancer Immunity
Alycia Gardner et al.
TRENDS IN IMMUNOLOGY (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Crosstalk between the HIF-1 and toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment
Han Shengwei et al.
ONCOTARGET (2016)
Hypoxia and antitumor CD8+ T cells: An incompatible alliance?
Romain Vuillefroy de Silly et al.
ONCOIMMUNOLOGY (2016)
Carbonic Anhydrase IX Promotes Myeloid-Derived Suppressor Cell Mobilization and Establishment of a Metastatic Niche by Stimulating G-CSF Production
Shawn C. Chafe et al.
CANCER RESEARCH (2015)
Does ramucirumab deserve a second chance for liver cancer?
Alejandro Forner et al.
LANCET ONCOLOGY (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model
Tao Yin et al.
ONCOLOGY RESEARCH (2015)
Co-stimulatory blockade of the CD28/CD80-86/CTLA-4 balance in transplantation: impact on memory T cells?
Simon Ville et al.
FRONTIERS IN IMMUNOLOGY (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
Tiansuo Zhao et al.
ONCOTARGET (2015)
Pattern Recognition Receptors in Cancer Progression and Metastasis
Sanjay Pandey et al.
CANCER GROWTH AND METASTASIS (2015)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
SIRT1 Limits the Function and Fate of Myeloid-Derived Suppressor Cells in Tumors by Orchestrating HIF-1α-Dependent Glycolysis
Guangwei Liu et al.
CANCER RESEARCH (2014)
Mechanisms of Hypoxia-Mediated Immune Escape in Cancer
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts
Massimo Ammirante et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
R. Kang et al.
CELL DEATH & DISEASE (2014)
Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro
Jouko Sandholm et al.
ONCOLOGY LETTERS (2014)
RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis
Mathias Dahlmann et al.
ONCOTARGET (2014)
Cancer: a tale of aberrant PRR response
Raunaq Singh Nagi et al.
FRONTIERS IN IMMUNOLOGY (2014)
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Brandon Faubert et al.
CELL METABOLISM (2013)
Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
Andrew L. Doedens et al.
NATURE IMMUNOLOGY (2013)
Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment
Koichi Ito et al.
CANCER AND METASTASIS REVIEWS (2012)
Hypoxia-inducible factor as a therapeutic target for cardioprotection
Sang-Ging Ong et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Targeting pattern recognition receptors in cancer immunotherapy
Nadege Goutagny et al.
TARGETED ONCOLOGY (2012)
Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression
Muhammad Zaeem Noman et al.
CANCER RESEARCH (2011)
CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts
Begona Santiago et al.
CYTOKINE (2011)
The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells
Emilie Narni-Mancinelli et al.
INTERNATIONAL IMMUNOLOGY (2011)
Hypoxia-Dependent Inhibition of Tumor Cell Susceptibility to CTL-Mediated Lysis Involves NANOG Induction in Target Cells
Meriem Hasmim et al.
JOURNAL OF IMMUNOLOGY (2011)
Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor Progression
Andrew L. Doedens et al.
CANCER RESEARCH (2010)
Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses
Christian Werno et al.
CARCINOGENESIS (2010)
HIF-1: upstream and downstream of cancer metabolism
Gregg L. Semenza
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Cesar A. Corzo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Toll-like Receptor 3 Regulates Angiogenesis and Apoptosis in Prostate Cancer Cell Lines through Hypoxia-Inducible Factor 1α
Alessio Paone et al.
NEOPLASIA (2010)
分享论文
